Review



hsc4  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC hsc4
    Hsc4, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hsc4/product/ATCC
    Average 94 stars, based on 42 article reviews
    hsc4 - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    hsc4  (ATCC)
    94
    ATCC hsc4
    Hsc4, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hsc4/product/ATCC
    Average 94 stars, based on 1 article reviews
    hsc4 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    JCRB Cell Bank hsc4 cell line
    2D cell culture conditions.
    Hsc4 Cell Line, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hsc4 cell line/product/JCRB Cell Bank
    Average 90 stars, based on 1 article reviews
    hsc4 cell line - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    JCRB Cell Bank human oscc cell line hsc4
    2D cell culture conditions.
    Human Oscc Cell Line Hsc4, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human oscc cell line hsc4/product/JCRB Cell Bank
    Average 90 stars, based on 1 article reviews
    human oscc cell line hsc4 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    JCRB Cell Bank hsc4 (rrid: cvcl_1289)
    2D cell culture conditions.
    Hsc4 (Rrid: Cvcl 1289), supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hsc4 (rrid: cvcl_1289)/product/JCRB Cell Bank
    Average 90 stars, based on 1 article reviews
    hsc4 (rrid: cvcl_1289) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    JCRB Cell Bank human head and neck squamous cancer cell line from cervical lymph node metastasis hsc4
    2D cell culture conditions.
    Human Head And Neck Squamous Cancer Cell Line From Cervical Lymph Node Metastasis Hsc4, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human head and neck squamous cancer cell line from cervical lymph node metastasis hsc4/product/JCRB Cell Bank
    Average 90 stars, based on 1 article reviews
    human head and neck squamous cancer cell line from cervical lymph node metastasis hsc4 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    JCRB Cell Bank human head and neck squamous cancer cell line hsc4
    2D cell culture conditions.
    Human Head And Neck Squamous Cancer Cell Line Hsc4, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human head and neck squamous cancer cell line hsc4/product/JCRB Cell Bank
    Average 90 stars, based on 1 article reviews
    human head and neck squamous cancer cell line hsc4 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Eppendorf AG hsc4 cell line
    Treatment scheme of HNSCC cell lines. HPV-negative <t>(HSC4,</t> Cal-33) and HPV-positive (UM-SCC-47, UD-SCC-2) HNSCC cells were seeded on day 1 and treated with 1µM AZD0156 or 0,1 µM VE-822 24 hours later. Irradiation with 5 Gy was performed 3 hours after treatment with smKI and repeated 24 hours later. Cells were harvested and analyzed 24 hours after the last treatment.
    Hsc4 Cell Line, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hsc4 cell line/product/Eppendorf AG
    Average 90 stars, based on 1 article reviews
    hsc4 cell line - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    2D cell culture conditions.

    Journal: Scientific Data

    Article Title: The Spheroid Light Microscopy Image Atlas for morphometrical analysis of three-dimensional cell cultures

    doi: 10.1038/s41597-025-04441-x

    Figure Lengend Snippet: 2D cell culture conditions.

    Article Snippet: HSC4 , JCRB/HSRRB (Japan) , DMEM LG , 1 , 1 , 25 , — , FBS , 10 , Yes , 5 , Yes.

    Techniques: Cell Culture, Concentration Assay, Transfection

    Treatment scheme of HNSCC cell lines. HPV-negative (HSC4, Cal-33) and HPV-positive (UM-SCC-47, UD-SCC-2) HNSCC cells were seeded on day 1 and treated with 1µM AZD0156 or 0,1 µM VE-822 24 hours later. Irradiation with 5 Gy was performed 3 hours after treatment with smKI and repeated 24 hours later. Cells were harvested and analyzed 24 hours after the last treatment.

    Journal: Frontiers in Oncology

    Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC

    doi: 10.3389/fonc.2024.1460150

    Figure Lengend Snippet: Treatment scheme of HNSCC cell lines. HPV-negative (HSC4, Cal-33) and HPV-positive (UM-SCC-47, UD-SCC-2) HNSCC cells were seeded on day 1 and treated with 1µM AZD0156 or 0,1 µM VE-822 24 hours later. Irradiation with 5 Gy was performed 3 hours after treatment with smKI and repeated 24 hours later. Cells were harvested and analyzed 24 hours after the last treatment.

    Article Snippet: Two HPV-negative HSC4 (RRID: CVCL_1289), Cal-33 (RRID: CVCL_1108) and two HPV-positive UM-SCC-47 (RRID: CVCL_7759), UD-SCC-2 (RRID: CVCL_E325) HNSCC cell lines were generously provided by Dr. Thorsten Rieckmann at the University Medical Center Hamburg-Eppendorf.

    Techniques: Irradiation

    Cell death analysis of HNSCC treated with ATMi or ATRi w/o 2x5Gy RT. RT combined with ATRi shows the highest toxicity in HNSCC cells, regardless of the HPV status. 48 hours post-RT, HPV-negative HSC4 (A) and Cal-33 (B) cells as well as HPV-positive UM-SCC-47 (C) and UD-SCC-2 (D) cells were identified as viable (AnnexinV-, PI-), apoptotic (AnnexinV+, PI-) or necrotic (AnnexinV+, PI+). Percentages of viable, apoptotic, and necrotic cells are shown as stacked bars representing the mean ± SD. A one-tailed Mann-Whitney U test was performed to compare the different treatment approaches within one cell line: *p ≤ 0.05, n=4.

    Journal: Frontiers in Oncology

    Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC

    doi: 10.3389/fonc.2024.1460150

    Figure Lengend Snippet: Cell death analysis of HNSCC treated with ATMi or ATRi w/o 2x5Gy RT. RT combined with ATRi shows the highest toxicity in HNSCC cells, regardless of the HPV status. 48 hours post-RT, HPV-negative HSC4 (A) and Cal-33 (B) cells as well as HPV-positive UM-SCC-47 (C) and UD-SCC-2 (D) cells were identified as viable (AnnexinV-, PI-), apoptotic (AnnexinV+, PI-) or necrotic (AnnexinV+, PI+). Percentages of viable, apoptotic, and necrotic cells are shown as stacked bars representing the mean ± SD. A one-tailed Mann-Whitney U test was performed to compare the different treatment approaches within one cell line: *p ≤ 0.05, n=4.

    Article Snippet: Two HPV-negative HSC4 (RRID: CVCL_1289), Cal-33 (RRID: CVCL_1108) and two HPV-positive UM-SCC-47 (RRID: CVCL_7759), UD-SCC-2 (RRID: CVCL_E325) HNSCC cell lines were generously provided by Dr. Thorsten Rieckmann at the University Medical Center Hamburg-Eppendorf.

    Techniques: One-tailed Test, MANN-WHITNEY

    Flow cytometric analysis of immune checkpoint surface marker on HNSCC after ATMi or ATRi w/o 2x5Gy RT. Combining RT with ATRi leads to the upregulation of immunostimulatory ICOS-L and CD137-L on HNSCC cells, irrespective of the HPV status. 48 hours after the last treatment, the HNSCC cells were harvested and the expression of immunostimulatory ICMs ICOS-L and CD137-L was examined by flow cytometry. The gating strategy is presented in (A) ICM expression is presented as ΔMFI (delta of mean fluorescence intensity of stained samples – background fluorescence) (B, C) . The combined treatment of RT and ATRi increased ICOS-L expression in all four cell lines compared to ATRi or RT alone, as well as in comparison to RT combined with ATMi (B) . Dual treatment with RT and ATMi tended to even decrease ICOS-L surface expression compared to RT or RT with ATRi (B) . RT and ATRi led to enhanced expression of immunostimulatory CD137-L in HPV-negative HSC4 cells compared to ATRi or RT alone, or the combined treatment of RT and ATMi (C) . In HPV-positive UM-SCC-47 and UD-SCC-2 cells, the combination of RT and ATRi also demonstrated higher surface expression of CD137-L compared to RT alone or treatment with RT and ATMi, respectively (C) . A one-tailed Mann-Whitney U test was performed to compare the different treatment approaches within one cell line: *p ≤ 0.05, n=4.

    Journal: Frontiers in Oncology

    Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC

    doi: 10.3389/fonc.2024.1460150

    Figure Lengend Snippet: Flow cytometric analysis of immune checkpoint surface marker on HNSCC after ATMi or ATRi w/o 2x5Gy RT. Combining RT with ATRi leads to the upregulation of immunostimulatory ICOS-L and CD137-L on HNSCC cells, irrespective of the HPV status. 48 hours after the last treatment, the HNSCC cells were harvested and the expression of immunostimulatory ICMs ICOS-L and CD137-L was examined by flow cytometry. The gating strategy is presented in (A) ICM expression is presented as ΔMFI (delta of mean fluorescence intensity of stained samples – background fluorescence) (B, C) . The combined treatment of RT and ATRi increased ICOS-L expression in all four cell lines compared to ATRi or RT alone, as well as in comparison to RT combined with ATMi (B) . Dual treatment with RT and ATMi tended to even decrease ICOS-L surface expression compared to RT or RT with ATRi (B) . RT and ATRi led to enhanced expression of immunostimulatory CD137-L in HPV-negative HSC4 cells compared to ATRi or RT alone, or the combined treatment of RT and ATMi (C) . In HPV-positive UM-SCC-47 and UD-SCC-2 cells, the combination of RT and ATRi also demonstrated higher surface expression of CD137-L compared to RT alone or treatment with RT and ATMi, respectively (C) . A one-tailed Mann-Whitney U test was performed to compare the different treatment approaches within one cell line: *p ≤ 0.05, n=4.

    Article Snippet: Two HPV-negative HSC4 (RRID: CVCL_1289), Cal-33 (RRID: CVCL_1108) and two HPV-positive UM-SCC-47 (RRID: CVCL_7759), UD-SCC-2 (RRID: CVCL_E325) HNSCC cell lines were generously provided by Dr. Thorsten Rieckmann at the University Medical Center Hamburg-Eppendorf.

    Techniques: Marker, Expressing, Flow Cytometry, Fluorescence, Staining, Comparison, One-tailed Test, MANN-WHITNEY